$5313 | SAVE $937 | Single User
$10625 | SAVE $1,875 | Site License
$15938 | SAVE $2,812 | Enterprise License

Ulcerative Colitis - Market Insight, Epidemiology and Market Forecast - 2027

Ulcerative Colitis (UC) - Market Insight, Epidemiology and Market Forecast - 2027
[Lowest Price Guaranteed: $5,313]

Published by Delve Insight: 14 Feb 2018 | 202044 | In Stock
Related Topics: Business , Drug , Ulcerative Colitis

Introduction

DelveInsight's "Ulcerative Colitis (UC) - Market Insight, Epidemiology and Market Forecast - 2027" report provides a detailed analysis of the Ulcerative Colitis (UC) epidemiology and market outlook for the 7MM.

Markets Covered

• United States

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan

Study Period: 2016-2027

Ulcerative Colitis (UC) Understanding and Treatment Algorithm

The market report provides the overview of the Ulcerative Colitis (UC) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Ulcerative Colitis (UC) Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2018 to 2027 segmented by seven major markets, enabling to understand the potential of the Ulcerative Colitis (UC) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Ulcerative Colitis (UC) Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Ulcerative Colitis (UC) Market Outlook

The report’s market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Ulcerative Colitis (UC) market.

Ulcerative Colitis (UC) Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2027. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Ulcerative Colitis (UC) Report Insights

• Patient Population in Ulcerative Colitis (UC)

• Therapeutic Approaches in Ulcerative Colitis (UC)

• Ulcerative Colitis (UC) Pipeline Analysis

• Ulcerative Colitis (UC) Market Size and Trends

• Ulcerative Colitis (UC) Market Opportunities

• Impact of upcoming Therapies in Ulcerative Colitis (UC)

Ulcerative Colitis (UC) Report Key Strengths

• 10 Year Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Drugs Uptake

• Highly Analyzed Market

• Key Cross Competition

Ulcerative Colitis (UC) Report Assessment

• Current Treatment Practices in Ulcerative Colitis (UC)

• Unmet Needs in Ulcerative Colitis (UC)

• Market Attractiveness

• Market Drivers and Barriers

Key Benefits

• The report will help to develop Business Strategies by understanding the trends shaping and driving the Ulcerative Colitis (UC) market

• Organize sales and marketing efforts by identifying the best opportunities for Ulcerative Colitis (UC) market

• To understand the future market competition in the Ulcerative Colitis (UC) market.

Table of Contents
for Ulcerative Colitis (UC) - Market Insight, Epidemiology and Market Forecast - 2027

  • 1. Report Introduction

    2. Ulcerative Colitis (UC) Market Overview at a Glance

    2.1. Market Share Distribution of Ulcerative Colitis (UC) in 2017

    2.2. Market Share Distribution of Ulcerative Colitis (UC) in 2027

    3. Disease Background and Overview: Ulcerative Colitis (UC)

    3.1. Introduction

    3.2. Symptoms

    3.3. Etiology

    3.4. Risk Factors

    3.5. Pathophysiology

    3.6. Diagnosis

    3.7. Treatment

    4. Epidemiology and Patient Population

    4.1. Key Findings

    4.2. Total Prevalent/ Incident Patient Population of Ulcerative Colitis (UC) in 7MM

    4.3. Total Prevalent Patient Population of Ulcerative Colitis (UC) in 7MM – By Countries

    5. Epidemiology of Ulcerative Colitis (UC) by Countries

    5.1. United States

    5.1.1. Assumptions and Rationale

    5.1.2. Prevalent/Incident Cases of the Ulcerative Colitis (UC)

    5.1.3. Sub-Type Specific cases of the Ulcerative Colitis (UC) *

    5.1.4. Sex- Specific Cases of the Ulcerative Colitis (UC) *

    5.1.5. Diagnosed Cases of the Ulcerative Colitis (UC)

    5.1.6. Treatable Cases of the Ulcerative Colitis (UC)

    5.2. EU5

    5.3. Assumptions and Rationale

    5.4. Germany

    5.4.1. Assumptions and Rationale

    5.4.2. Prevalent/Incident Cases of the Ulcerative Colitis (UC)

    5.4.3. Sub-Type Specific cases of the Ulcerative Colitis (UC) *

    5.4.4. Sex- Specific Cases of the Ulcerative Colitis (UC) *

    5.4.5. Diagnosed Cases of the Ulcerative Colitis (UC)

    5.4.6. Treatable Cases of the Ulcerative Colitis (UC)

    5.5. France

    5.5.1. Assumptions and Rationale

    5.5.2. Prevalent/Incident Cases of the Ulcerative Colitis (UC)

    5.5.3. Sub-Type Specific cases of the Ulcerative Colitis (UC) *

    5.5.4. Sex- Specific Cases of the Ulcerative Colitis (UC) *

    5.5.5. Diagnosed Cases of the Ulcerative Colitis (UC)

    5.5.6. Treatable Cases of the Ulcerative Colitis (UC)

    5.6. Italy

    5.6.1. Assumptions and Rationale

    5.6.2. Prevalent/Incident Cases of the Ulcerative Colitis (UC)

    5.6.3. Sub-Type Specific cases of the Ulcerative Colitis (UC) *

    5.6.4. Sex- Specific Cases of the Ulcerative Colitis (UC) *

    5.6.5. Diagnosed Cases of the Ulcerative Colitis (UC)

    5.6.6. Treatable Cases of the Ulcerative Colitis (UC)

    5.7. Spain

    5.7.1. Assumptions and Rationale

    5.7.2. Prevalent/Incident Cases of the Ulcerative Colitis (UC)

    5.7.3. Sub-Type Specific cases of the Ulcerative Colitis (UC) *

    5.7.4. Sex- Specific Cases of the Ulcerative Colitis (UC) *

    5.7.5. Diagnosed Cases of the Ulcerative Colitis (UC)

    5.7.6. Treatable Cases of the Ulcerative Colitis (UC)

    5.8. United Kingdom

    5.8.1. Assumptions and Rationale

    5.8.2. Prevalent/Incident Cases of the Ulcerative Colitis (UC)

    5.8.3. Sub-Type Specific cases of the Ulcerative Colitis (UC) *

    5.8.4. Sex- Specific Cases of the Ulcerative Colitis (UC) *

    5.8.5. Diagnosed Cases of the Ulcerative Colitis (UC)

    5.8.6. Treatable Cases of the Ulcerative Colitis (UC)

    5.9. Japan

    5.9.1. Assumptions and Rationale

    5.9.2. Prevalent/Incident Cases of the Ulcerative Colitis (UC)

    5.9.3. Sub-Type Specific cases of the Ulcerative Colitis (UC) *

    5.9.4. Sex- Specific Cases of the Ulcerative Colitis (UC) *

    5.9.5. Diagnosed Cases of the Ulcerative Colitis (UC)

    5.9.6. Treatable Cases of the Ulcerative Colitis (UC)

    6. Current Treatment & Medical practices

    6.1. Treatment Algorithm

    6.2. Treatment Guidelines

    7. Unmet Needs of the Ulcerative Colitis (UC)

    8. Marketed Therapies

    8.1. Drug A: Company 1

    8.1.1. Drug Description

    8.1.2. Mechanism of Action

    8.1.3. Regulatory Milestones

    8.1.4. Advantages & Disadvantages

    8.1.5. Product Profile

    8.2. Drug B: Company 2

    8.2.1. Drug Description

    8.2.2. Mechanism of Action

    8.2.3. Regulatory Milestones

    8.2.4. Advantages & Disadvantages

    8.2.5. Product Profile

    9. Pipeline Therapies – At a glance

    10. Key Cross Competition

    11. Emerging Therapies for Ulcerative Colitis (UC)

    11.1. Drug C: Company 3

    11.1.1. Drug Description

    11.1.2. Clinical Trials Details

    11.1.3. Safety and Efficacy Profile

    11.1.4. Advantages & Disadvantages

    11.1.5. Pipeline Development Activities

    11.1.6. Product Profile

    11.2. Drug D: Company 4

    11.2.1. Drug Description

    11.2.2. Clinical Trials Details

    11.2.3. Safety and Efficacy Profile

    11.2.4. Advantages & Disadvantages

    11.2.5. Pipeline Development Activities

    11.2.6. Product Profile

    12. Ulcerative Colitis (UC) : 7MM Market Analysis

    12.1. 7MM Market Size of Ulcerative Colitis (UC)

    12.2. 7MM Percentage Share of drugs marketed for Ulcerative Colitis (UC)

    12.3. 7MM Market Sales of Ulcerative Colitis (UC) by Products

    13. Ulcerative Colitis (UC) : Country-Wise Market Analysis

    13.1. United States

    13.1.1. Market Size of Ulcerative Colitis (UC) in United States

    13.1.2. Percentage Share of drugs marketed for Ulcerative Colitis (UC) in United States

    13.1.3. Market Sales of Ulcerative Colitis (UC) by Products in United States

    13.1.4. Analysis of Upcoming Therapies and their Impact on the Market

    13.2. EU-5

    13.2.1. Germany

    13.2.1.1. Market Size of Ulcerative Colitis (UC) in Germany

    13.2.1.2. Percentage Share of drugs marketed for Ulcerative Colitis (UC) in Germany

    13.2.1.3. Market Sales of Ulcerative Colitis (UC) by Products in Germany

    13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market

    13.2.2. France

    13.2.2.1. Market Size of Ulcerative Colitis (UC) in France

    13.2.2.2. Percentage Share of drugs marketed for Ulcerative Colitis (UC) in France

    13.2.2.3. Market Sales of Ulcerative Colitis (UC) by Products in France

    13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market

    13.2.3. Italy

    13.2.3.1. Market Size of Ulcerative Colitis (UC) in Italy

    13.2.3.2. Percentage Share of drugs marketed for Ulcerative Colitis (UC) in Italy

    13.2.3.3. Market Sales of Ulcerative Colitis (UC) by Products in Italy

    13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market

    13.2.4. Spain

    13.2.4.1. Market Size of Ulcerative Colitis (UC) in Spain

    13.2.4.2. Percentage Share of drugs marketed for Ulcerative Colitis (UC) in Spain

    13.2.4.3. Market Sales of Ulcerative Colitis (UC) by Products in Spain

    13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market

    13.2.5. United Kingdom

    13.2.5.1. Market Size of Ulcerative Colitis (UC) in United Kingdom

    13.2.5.2. Percentage Share of drugs marketed for Ulcerative Colitis (UC) in United Kingdom

    13.2.5.3. Market Sales of Ulcerative Colitis (UC) by Products in United Kingdom

    13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market

    13.3. Japan

    13.3.1. Market Size of Ulcerative Colitis (UC) in Japan

    13.3.2. Percentage Share of drugs marketed for Ulcerative Colitis (UC) in Japan

    13.3.3. Market Sales of Ulcerative Colitis (UC) by Products in Japan

    13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

    14. Market Drivers

    15. Market Barriers

    16. Appendix

    17. Report Methodology

    17.1. Sources

    18. DelveInsight Capabilities

    19. Disclaimer

    20. About DelveInsight

    *Indication Specific

List Of Tables
in Ulcerative Colitis - Market Insight, Epidemiology and Market Forecast - 2027

Table 1: Total Prevalent/Incident Cases of the Ulcerative Colitis (UC) in 7MM

Table 2: Total Prevalent/Incident Cases of the Ulcerative Colitis (UC) in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Ulcerative Colitis (UC) in United States (2016-2027)

Table 4: Sub-Type Specific cases of the Ulcerative Colitis (UC) in United States (2016-2027)

Table 5: Sex- Specific Cases of the Ulcerative Colitis (UC) in United States (2016-2027)

Table 6: Diagnosed Cases of the Ulcerative Colitis (UC) in United States (2016-2027)

Table 7: Treatable Cases of the Ulcerative Colitis (UC) in United States (2016-2027)

Table 8: Prevalent/Incident Cases of the Ulcerative Colitis (UC) in Germany (2016-2027)

Table 9: Sub-Type Specific cases of the Ulcerative Colitis (UC) in Germany (2016-2027)

Table 10: Sex- Specific Cases of the Ulcerative Colitis (UC) in Germany (2016-2027)

Table 11: Diagnosed Cases of the Ulcerative Colitis (UC) in Germany (2016-2027)

Table 12: Treatable Cases of the Ulcerative Colitis (UC) in Germany (2016-2027)

Table 13: Prevalent/Incident Cases of the Ulcerative Colitis (UC) in France (2016-2027)

Table 14: Sub-Type Specific cases of the Ulcerative Colitis (UC) in France (2016-2027)

Table 15: Sex- Specific Cases of the Ulcerative Colitis (UC) in France (2016-2027)

Table 16: Diagnosed Cases of the Ulcerative Colitis (UC) in France (2016-2027)

Table 17: Treatable Cases of the Ulcerative Colitis (UC) in France (2016-2027)

Table 18: Prevalent/Incident Cases of the Ulcerative Colitis (UC) in Italy (2016-2027)

Table 19: Sub-Type Specific cases of the Ulcerative Colitis (UC) in Italy (2016-2027)

Table 20: Sex- Specific Cases of the Ulcerative Colitis (UC) in Italy (2016-2027)

Table 21: Diagnosed Cases of the Ulcerative Colitis (UC) in Italy (2016-2027)

Table 22: Treatable Cases of the Ulcerative Colitis (UC) in Italy (2016-2027)

Table 23: Prevalent/Incident Cases of the Ulcerative Colitis (UC) in Spain (2016-2027)

Table 24: Sub-Type Specific cases of the Ulcerative Colitis (UC) in Spain (2016-2027)

Table 25: Sex- Specific Cases of the Ulcerative Colitis (UC) in Spain (2016-2027)

Table 26: Diagnosed Cases of the Ulcerative Colitis (UC) in Spain (2016-2027)

Table 27: Treatable Cases of the Ulcerative Colitis (UC) in Spain (2016-2027)

Table 28: Prevalent/Incident Cases of the Ulcerative Colitis (UC) in UK (2016-2027)

Table 29: Sub-Type Specific cases of the Ulcerative Colitis (UC) in UK (2016-2027)

Table 30: Sex- Specific Cases of the Ulcerative Colitis (UC) in UK (2016-2027)

Table 31: Diagnosed Cases of the Ulcerative Colitis (UC) in UK (2016-2027)

Table 32: Treatable Cases of the Ulcerative Colitis (UC) in UK (2016-2027)

Table 33: Prevalent/Incident Cases of the Ulcerative Colitis (UC) in Japan (2016-2027)

Table 34: Sub-Type Specific cases of the Ulcerative Colitis (UC) in Japan (2016-2027)

Table 35: Sex- Specific Cases of the Ulcerative Colitis (UC) in Japan (2016-2027)

Table 36: Diagnosed Cases of the Ulcerative Colitis (UC) in Japan (2016-2027)

Table 37: Treatable Cases of the Ulcerative Colitis (UC) in Japan (2016-2027)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Ulcerative Colitis (UC) in USD MM (2016-2027)

Table 42:7MM- Market Share Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Table 43:7MM- Market Sales of Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Table 44: United States-Market Size of Ulcerative Colitis (UC) in USD MM (2016-2027)

Table 45: United States-Market Share Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Table 46: United States-Market Sales of Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Table 47: Germany-Market Size of Ulcerative Colitis (UC) in USD MM (2016-2027)

Table 48: Germany-Market Share Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Table 49: Germany-Market Sales of Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Table 50: France-Market Size of Ulcerative Colitis (UC) in USD MM (2016-2027)

Table 51: France-Market Share Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Table 52: France-Market Sales of Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Table 53: Italy-Market Size of Ulcerative Colitis (UC) in USD MM (2016-2027)

Table 54: Italy-Market Share Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Table 55: Italy-Market Sales of Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Table 56: Spain-Market Size of Ulcerative Colitis (UC) in USD MM (2016-2027)

Table 57: Spain-Market Share Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Table 58: Spain-Market Sales of Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Table 59:UK-Market Size of Ulcerative Colitis (UC) in USD MM (2016-2027)

Table 60:UK-Market Share Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Table 61:UK-Market Sales of Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Table 62: Japan-Market Size of Ulcerative Colitis (UC) in USD MM (2016-2027)

Table 63: Japan-Market Share Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Table 64: Japan-Market Sales of Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

List Of Figures, Charts and Diagrams
in Ulcerative Colitis - Market Insight, Epidemiology and Market Forecast - 2027

Figure 1: Total Prevalent/Incident Cases of the Ulcerative Colitis (UC) in 7MM

Figure 2: Total Prevalent/Incident Cases of the Ulcerative Colitis (UC) in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Ulcerative Colitis (UC) in United States (2016-2027)

Figure 4: Sub-Type Specific cases of the Ulcerative Colitis (UC) in United States (2016-2027)

Figure 5: Sex- Specific Cases of the Ulcerative Colitis (UC) in United States (2016-2027)

Figure 6: Diagnosed Cases of the Ulcerative Colitis (UC) in United States (2016-2027)

Figure 7: Treatable Cases of the Ulcerative Colitis (UC) in United States (2016-2027)

Figure 8: Prevalent/Incident Cases of the Ulcerative Colitis (UC) in Germany (2016-2027)

Figure 9: Sub-Type Specific cases of the Ulcerative Colitis (UC) in Germany (2016-2027)

Figure 10: Sex- Specific Cases of the Ulcerative Colitis (UC) in Germany (2016-2027)

Figure 11: Diagnosed Cases of the Ulcerative Colitis (UC) in Germany (2016-2027)

Figure 12: Treatable Cases of the Ulcerative Colitis (UC) in Germany (2016-2027)

Figure 13: Prevalent/Incident Cases of the Ulcerative Colitis (UC) in France (2016-2027)

Figure 14: Sub-Type Specific cases of the Ulcerative Colitis (UC) in France (2016-2027)

Figure 15: Sex- Specific Cases of the Ulcerative Colitis (UC) in France (2016-2027)

Figure 16: Diagnosed Cases of the Ulcerative Colitis (UC) in France (2016-2027)

Figure 17: Treatable Cases of the Ulcerative Colitis (UC) in France (2016-2027)

Figure 18: Prevalent/Incident Cases of the Ulcerative Colitis (UC) in Italy (2016-2027)

Figure 19: Sub-Type Specific cases of the Ulcerative Colitis (UC) in Italy (2016-2027)

Figure 20: Sex- Specific Cases of the Ulcerative Colitis (UC) in Italy (2016-2027)

Figure 21: Diagnosed Cases of the Ulcerative Colitis (UC) in Italy (2016-2027)

Figure 22: Treatable Cases of the Ulcerative Colitis (UC) in Italy (2016-2027)

Figure 23: Prevalent/Incident Cases of the Ulcerative Colitis (UC) in Spain (2016-2027)

Figure 24: Sub-Type Specific cases of the Ulcerative Colitis (UC) in Spain (2016-2027)

Figure 25: Sex- Specific Cases of the Ulcerative Colitis (UC) in Spain (2016-2027)

Figure 26: Diagnosed Cases of the Ulcerative Colitis (UC) in Spain (2016-2027)

Figure 27: Treatable Cases of the Ulcerative Colitis (UC) in Spain (2016-2027)

Figure 28: Prevalent/Incident Cases of the Ulcerative Colitis (UC) in UK (2016-2027)

Figure 29: Sub-Type Specific cases of the Ulcerative Colitis (UC) in UK (2016-2027)

Figure 30: Sex- Specific Cases of the Ulcerative Colitis (UC) in UK (2016-2027)

Figure 31: Diagnosed Cases of the Ulcerative Colitis (UC) in UK (2016-2027)

Figure 32: Treatable Cases of the Ulcerative Colitis (UC) in UK (2016-2027)

Figure 33: Prevalent/Incident Cases of the Ulcerative Colitis (UC) in Japan (2016-2027)

Figure 34: Sub-Type Specific cases of the Ulcerative Colitis (UC) in Japan (2016-2027)

Figure 35: Sex- Specific Cases of the Ulcerative Colitis (UC) in Japan (2016-2027)

Figure 36: Diagnosed Cases of the Ulcerative Colitis (UC) in Japan (2016-2027)

Figure 37: Treatable Cases of the Ulcerative Colitis (UC) in Japan (2016-2027)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Ulcerative Colitis (UC) in USD MM (2016-2027)

Figure 42:7MM- Market Share Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Figure 43:7MM- Market Sales of Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Figure 44: United States-Market Size of Ulcerative Colitis (UC) in USD MM (2016-2027)

Figure 45: United States-Market Share Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Figure 46: United States-Market Sales of Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Figure 47: Germany-Market Size of Ulcerative Colitis (UC) in USD MM (2016-2027)

Figure 48: Germany-Market Share Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Figure 49: Germany-Market Sales of Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Figure 50: France-Market Size of Ulcerative Colitis (UC) in USD MM (2016-2027)

Figure 51: France-Market Share Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Figure 52: France-Market Sales of Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Figure 53: Italy-Market Size of Ulcerative Colitis (UC) in USD MM (2016-2027)

Figure 54: Italy-Market Share Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Figure 55: Italy-Market Sales of Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Figure 56: Spain-Market Size of Ulcerative Colitis (UC) in USD MM (2016-2027)

Figure 57: Spain-Market Share Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Figure 58: Spain-Market Sales of Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Figure 59:UK-Market Size of Ulcerative Colitis (UC) in USD MM (2016-2027)

Figure 60:UK-Market Share Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Figure 61:UK-Market Sales of Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Figure 62: Japan-Market Size of Ulcerative Colitis (UC) in USD MM (2016-2027)

Figure 63: Japan-Market Share Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Figure 64: Japan-Market Sales of Ulcerative Colitis (UC) by Therapies in USD MM (2016-2027)

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

202044 | DIMI0345

Number of Pages

100

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Ulcerative Colitis - Pipeline Review, H1 2017
Ulcerative Colitis - Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical an...
09 May 2017 by Global Markets Direct USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2017
The Global Ulcerative Colitis Partnering Terms and Agreements since 2010 report provides understandi...
01 Apr 2017 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2017
The Global Ulcerative Colitis Partnering Terms and Agreements since 2010 report provides understandi...
01 Feb 2017 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Nov 2016 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Ulcerative Colitis Global Clinical Trials Review, H2, 2016
Ulcerative Colitis Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report,...
28 Sep 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Ulcerative Colitis: KOL Insight
Are UC biosimilars a real or perceived threat to branded drugs?Ulcerative colitis (UC) treatment is ...
01 Sep 2016 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info
SAVE 15% today! Ulcerative Colitis: Update Bulletin [Feb 2016]
IntroductionGain new KOL insights on the latest events happening in Ulcerative Colitis. Topics cover...
01 Feb 2016 by FirstWord Pharma USD $846 (normally
USD $995)
More Info
SAVE 15% today! Ulcerative Colitis: KOL Insight
Introductionipeline drugs are poised to reshape the way doctors treat ulcerative colitis (UC). But w...
01 Dec 2015 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info
SAVE 15% today! Ulcerative Colitis: KOL Insight
IntroductionThe Ulcerative Colitis (UC) treatment market is already undergoing radical change as new...
03 Dec 2014 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Download Free Report Summary PDF

Ulcerative Colitis (UC) - Market Insight, Epidemiology and Market Forecast - 2027 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...